Adjunctive Treatment of Major Depressive Disorder
4
Pipeline Programs
1
Companies
3
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
PIMAVANSERINApproved
pimavanserin
Unknown Companyoral
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Acadia PharmaceuticalsSAN DIEGO, CA
3 programs1
2
PimavanserinPhase 31 trial
PimavanserinPhase 31 trial
PimavanserinPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
Acadia PharmaceuticalsPimavanserin
Acadia PharmaceuticalsPimavanserin
Clinical Trials (3)
Total enrollment: 740 patients across 3 trials
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Start: Jun 2019Est. completion: Feb 2021235 patients
Phase 3Terminated
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Start: Apr 2019Est. completion: May 2020298 patients
Phase 3Completed
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Start: Dec 2016Est. completion: Oct 2018207 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space